Response to Minimum Requirements for Reporting Clinical Trials Evaluating the Therapeutic Potential of Platelet-Rich Plasma

The authors, Lu Yin et al., responded to Sharun & Pawde's letter regarding their paper on platelet-rich plasma (PRP) as a treatment for androgenetic alopecia. They acknowledged the variability in PRP preparations and agreed that standardized reporting of PRP methods would benefit the comparison of results across studies. However, they noted that the relationship between PRP components and hair growth outcomes is not fully understood, and current guidelines do not account for all factors that may influence hair growth. They recommended that future PRP trials for androgenetic alopecia avoid a split-scalp design due to potential diffusion of PRP, suggesting instead that patients be assigned to either a placebo or PRP group. The authors welcomed the standardization of PRP preparation reporting to improve the analysis of studies, including randomized controlled trials.